REGN4336 is named as a drug or biological intervention in 2 clinical trials in our USA trial register, 2 of which are recruiting. The lead sponsor is Regeneron Pharmaceuticals. Registered phase: Phase 1/2. Conditions studied include Metastatic Castration-Resistant Prostate Cancer (mCRPC); Clear Cell Renal Cell Carcinoma (ccRCC); Metastatic Castration-resistant Prostate Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05125016 | A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer (ClinicalTrials.gov ↗) Metastatic Castration-resistant Prostate Cancer |
Phase 1/2 | Recruiting |
| NCT07594106 | REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) |
Phase 1/2 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 1 |
| Clear Cell Renal Cell Carcinoma (ccRCC) | 1 |
| Metastatic Castration-resistant Prostate Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Regeneron Pharmaceuticals | 2 |
| Register | REGN4336 trials |
|---|---|
| Clinical trials in USA | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how REGN4336 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists REGN4336 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.